Received Feb 3, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | Y020531 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No additional AE reported; Nurse called and reported that a patient received the second and third dose of GARDASIL9 too close together.; This Spontaneous report was received from Nurse and referred to a Female patient of unknown age. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. On 13-May-2025, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (1 dosage form, exact dose, route, strength, lot and expiration date were not reported) for prophylaxis. On 23-Oct-2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (1 dosage form, exact dose, route, strength, lot and expiration date were not reported). On 14-Nov-2025, the patient was vaccinated with the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (0.5 mL, Batch/Lot Number: Y020531 has been verified to be vaid lot, Expiration date: 05-Aug-2027; route and strength were not reported) (Inappropriate schedule of product administration). No additional AE reported (No adverse event). Lot# is being requested and will be submitted if received.